Marker Therapeutics, Inc. (MRKR)
0.8928
0.00 (0.00%)
USD |
NASDAQ |
Nov 06, 16:00
0.9166
+0.02
(+2.67%)
After-Hours: 20:00
Marker Therapeutics Enterprise Value : 2.963M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 2.963M |
| November 05, 2026 | 3.008M |
| November 04, 2026 | 4.918M |
| November 03, 2026 | 4.466M |
| November 02, 2026 | 3.102M |
| October 30, 2026 | 4.417M |
| October 29, 2026 | 4.918M |
| October 28, 2026 | 4.751M |
| October 27, 2026 | 3.939M |
| October 26, 2026 | 3.190M |
| October 23, 2026 | 4.086M |
| October 22, 2026 | 5.918M |
| October 21, 2026 | 6.918M |
| October 20, 2026 | 7.418M |
| October 19, 2026 | 8.085M |
| October 16, 2026 | 5.418M |
| October 15, 2026 | 3.417M |
| October 14, 2026 | 2.920M |
| October 13, 2026 | 3.499M |
| October 12, 2026 | 4.918M |
| October 09, 2026 | 4.277M |
| October 08, 2026 | 3.917M |
| October 07, 2026 | 5.418M |
| October 06, 2026 | 4.918M |
| October 05, 2026 | 5.751M |
| Date | Value |
|---|---|
| October 02, 2026 | 5.584M |
| October 01, 2026 | 5.584M |
| September 30, 2026 | 5.918M |
| September 29, 2026 | 6.418M |
| September 28, 2026 | 6.835M |
| September 25, 2026 | 7.252M |
| September 24, 2026 | 7.919M |
| September 23, 2026 | 8.752M |
| September 22, 2026 | 8.419M |
| September 21, 2026 | 8.085M |
| September 18, 2026 | 7.752M |
| September 17, 2026 | 7.752M |
| September 16, 2026 | 7.085M |
| September 15, 2026 | 7.585M |
| September 14, 2026 | 7.585M |
| September 11, 2026 | 7.252M |
| September 10, 2026 | 8.085M |
| September 09, 2026 | 8.252M |
| September 08, 2026 | 9.419M |
| September 04, 2026 | 7.752M |
| September 03, 2026 | 8.752M |
| September 02, 2026 | 8.919M |
| September 01, 2026 | 9.753M |
| August 31, 2026 | 10.25M |
| August 28, 2026 | 10.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Rigel Pharmaceuticals, Inc. | 684.25M |
| ACADIA Pharmaceuticals, Inc. | 2.735B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
| Anika Therapeutics, Inc. | 181.56M |
| Savara, Inc. | 849.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.826M |
| Total Expenses (Quarterly) | 1.826M |
| EPS Diluted (Quarterly) | -0.0946 |
| Earnings Yield | -53.84% |
| Normalized Earnings Yield | -53.83 |